Literature DB >> 20501939

Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation.

Tzu-Hao Wang1, Angel Chao, Chia-Lung Tsai, Chih-Long Chang, Shun-Hua Chen, Yun-Shien Lee, Jen-Kun Chen, Yi-Jun Lin, Pi-Yueh Chang, Chin-Jung Wang, An-Shine Chao, Shuenn-Dyh Chang, Ting-Chang Chang, Chyong-Huey Lai, Hsin-Shih Wang.   

Abstract

Ovarian cancers are frequently not diagnosed until advanced stages, resulting in a high case fatality rate. Because of this, more tumor markers, in addition to CA125, for detecting and monitoring ovarian cancer are needed. During a systematic search for potential biomarkers of ovarian cancer, we compared the protein profiles between tumor interstitial fluid and normal interstitial fluid of ovaries, rationalizing that abnormal levels of proteins in tumor interstitial fluid may be detected in peripheral blood and thus serve as easily accessible tumor markers. Here, we show that stress-induced phosphoprotein 1 (STIP1) was secreted by ovarian cancer tissues into the peripheral blood of patients, resulting in a significant increase of serum levels of STIP1 in cancer patients compared with those in age-matched normal controls. Our results further indicated that combined use of CA125 and STIP1 may increase early detection of ovarian cancer. Functionally, recombinant STIP1 significantly induced ERK phosphorylation, promoted DNA synthesis, and increased Ki-67 immunoreactivity in ovarian cancer cells, suggesting that STIP1 in vitro promotes cell proliferation. Colocalization of STIP1 and phospho-ERK in human ovarian cancer tissues also supports an in vivo activation of ERK by STIP1. Further understanding of molecular roles of STIP1 in human ovarian cancer may shed light on its pathophysiology and development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501939      PMCID: PMC2938116          DOI: 10.1074/mcp.M110.000802

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  40 in total

Review 1.  HUPO initiatives relevant to clinical proteomics.

Authors:  Sam Hanash
Journal:  Mol Cell Proteomics       Date:  2004-01-27       Impact factor: 5.911

2.  Comparative proteomic studies on the pathogenesis of human ulcerative colitis.

Authors:  Sen-Yung Hsieh; Tsung-Chieh Shih; Chien-Yuh Yeh; Chun-Jung Lin; Yun-Ying Chou; Ying-Shiung Lee
Journal:  Proteomics       Date:  2006-10       Impact factor: 3.984

3.  Clinical proteomics.

Authors:  Julio E Celis; José M A Moreira
Journal:  Mol Cell Proteomics       Date:  2008-10       Impact factor: 5.911

4.  Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

Authors:  B W Yin; K O Lloyd
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

5.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.

Authors:  Beatrice W T Yin; Ann Dnistrian; Kenneth O Lloyd
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

6.  Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells.

Authors:  T H Wang; D M Popp; H S Wang; M Saitoh; J G Mural; D C Henley; H Ichijo; J Wimalasena
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

Review 7.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

8.  Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.

Authors:  Franco Carta; Pietro P Demuro; Cristina Zanini; Antonella Santona; Daniele Castiglia; Stefania D'Atri; Paolo A Ascierto; Maria Napolitano; Antonio Cossu; Bruna Tadolini; Franco Turrini; Antonella Manca; Maria C Sini; Giuseppe Palmieri; And Carla Rozzo
Journal:  Melanoma Res       Date:  2005-08       Impact factor: 3.599

Review 9.  Genomic tests for ovarian cancer detection and management.

Authors:  Evan R Myers; Laura J Havrilesky; Shalini L Kulasingam; Gillian D Sanders; Kathryn E Cline; Rebecca N Gray; Andrew Berchuck; Douglas C McCrory
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2006-10

10.  Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.

Authors:  Xin Yi; John M Luk; Nikki P Lee; Jirun Peng; Xisheng Leng; Xin-Yuan Guan; George K Lau; Laura Beretta; Sheung-Tat Fan
Journal:  Mol Cell Proteomics       Date:  2007-10-14       Impact factor: 5.911

View more
  48 in total

1.  Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.

Authors:  M H Lopes; T G Santos; B R Rodrigues; N Queiroz-Hazarbassanov; I W Cunha; A P Wasilewska-Sampaio; B Costa-Silva; F A Marchi; L F Bleggi-Torres; P I Sanematsu; S H Suzuki; S M Oba-Shinjo; S K N Marie; E Toulmin; A F Hill; V R Martins
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

2.  The unconventional secretion of stress-inducible protein 1 by a heterogeneous population of extracellular vesicles.

Authors:  Glaucia N M Hajj; Camila P Arantes; Marcos Vinicios Salles Dias; Martín Roffé; Bruno Costa-Silva; Marilene H Lopes; Isabel Porto-Carreiro; Tatiana Rabachini; Flávia R Lima; Flávio H Beraldo; Marco A M Prado; Marco M A Prado; Rafael Linden; Vilma R Martins
Journal:  Cell Mol Life Sci       Date:  2013-03-31       Impact factor: 9.261

3.  Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Authors:  Satyendra C Tripathi; Haley L Peters; Ayumu Taguchi; Hiroyuki Katayama; Hong Wang; Amin Momin; Mohit Kumar Jolly; Muge Celiktas; Jaime Rodriguez-Canales; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Eshel Ben-Jacob; Herbert Levine; Jeffrey J Molldrem; Samir M Hanash; Edwin J Ostrin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

4.  Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages.

Authors:  Anna Carolina Carvalho da Fonseca; Huaqing Wang; Haitao Fan; Xuebo Chen; Ian Zhang; Leying Zhang; Flavia Regina Souza Lima; Behnam Badie
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

5.  Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines.

Authors:  Ogunc Meral; Hamdi Uysal
Journal:  Tumour Biol       Date:  2014-10-01

6.  HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature.

Authors:  Stacey A Mattison; Gregory L Blatch; Adrienne L Edkins
Journal:  Cell Stress Chaperones       Date:  2016-12-16       Impact factor: 3.667

7.  Apigenin inhibits growth and induces apoptosis in human cholangiocarcinoma cells.

Authors:  Pantipa Subhasitanont; Daranee Chokchaichamnankit; Khajeelak Chiablaem; Siriporn Keeratichamroen; Lukana Ngiwsara; N Monique Paricharttanakul; Kriengsak Lirdprapamongkol; Churat Weeraphan; Jisnuson Svasti; Chantragan Srisomsap
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

8.  Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer.

Authors:  Hanbyoul Cho; Sunghoon Kim; Ha-Yeon Shin; Eun Joo Chung; Haruhisa Kitano; Jae Hyon Park; Lucienne Park; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim
Journal:  Genes Chromosomes Cancer       Date:  2014-02-01       Impact factor: 5.006

9.  Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.

Authors:  Tianhong Su; Junbin Liao; Zihao Dai; Lixia Xu; Shuling Chen; Yifei Wang; Zhenwei Peng; Qiuyang Zhang; Sui Peng; Ming Kuang
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

10.  Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23).

Authors:  Angel Chao; Chiao-Yun Lin; Chia-Lung Tsai; Swei Hsueh; Ying-Yu Lin; Cheng-Tao Lin; Hung-Hsueh Chou; Tzu-Hao Wang; Chyong-Huey Lai; Hsin-Shih Wang
Journal:  J Mol Med (Berl)       Date:  2012-08-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.